2 results
Approved WMOCompleted
The key objective of this study is to assess next-day residual effects of MK-4305 (20 and 40 mg) via driving performance after 1 day of dosing and after 8 days of dosing.
Not approvedWill not start
Primary: To compare the efficacy of aripiprazole with placebo in the suppression of tics in children and adolescents (7-17 years) with a diagnosis of Tourette*s Disorder. The primary efficacy measure is change from Baseline to endpoint (Week 8) on…